Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAGNAR: Phase 2 Erdafitinib in Advanced Solid Tumors with FGFR Alterations
jRCT2080225109Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of erdafitinib in Nonhematologic neoplasms and Metastatic solid neoplasm, sponsored by Janssen Pharmaceutical. Started Mar 2020; status: completed.
02
Drugs
erdafitinib
03
Conditions
Nonhematologic neoplasmsMetastatic solid neoplasm
Beyond the preview
Go deeper on jRCT2080225109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225109.